What is Cure Pharmaceutical?
Founded in 2011 and headquartered in Oxnard, California, Cure Pharmaceutical operates as a technology-focused, vertically integrated drug delivery and product development enterprise. The company distinguishes itself by bridging the gap between traditional pharmaceutical manufacturing and advanced health and wellness solutions. By leveraging proprietary delivery technologies, Cure Pharmaceutical addresses complex challenges in bioavailability and patient compliance, effectively transforming how therapeutic agents are administered. Its market position is defined by a robust intellectual property portfolio and a commitment to optimizing drug efficacy through innovative formulation science.
How much funding has Cure Pharmaceutical raised?
Cure Pharmaceutical has raised a total of $19.3M across 5 funding rounds:
Debt
$2M
Debt
$958K
Debt
$6M
Debt
$350K
Share Placement
$10M
Debt (2011): $2M, investors not publicly disclosed
Debt (2012): $958K, investors not publicly disclosed
Debt (2015): $6M, investors not publicly disclosed
Debt (2020): $350K featuring PPP
Share Placement (2020): $10M, investors not publicly disclosed
Key Investors in Cure Pharmaceutical
PPP
Public-Private Partnership
Undisclosed Investor
An institutional participant providing capital to support the company's long-term strategic development and infrastructure expansion.
Undisclosed Investor
A private backer contributing to the firm's share placement initiatives to bolster its market presence in the pharmaceutical sector.
What's next for Cure Pharmaceutical?
With the recent infusion of $10M, Cure Pharmaceutical is well-positioned to accelerate its research and development pipeline and enhance its commercialization efforts. The company is expected to focus on scaling its manufacturing capacity to meet increasing demand for its specialized delivery platforms. Furthermore, the strategic nature of this funding suggests a pivot toward broader market penetration and potential partnerships that could leverage its unique technological assets. As the firm transitions into this next phase of enterprise-level growth, stakeholders will be monitoring its ability to translate these capital resources into sustained clinical and commercial success within the global pharmaceutical market.
See full Cure Pharmaceutical company page
